Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 02
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
ProQR Therapeutics NV
PRQR
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.63
-0.03
-1.81%
Dern. MÀJ: Oct 1, 7:35 PM
$1.64
-0.02
-1.2%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
ProQR Therapeutics Financials
ProQR Therapeutics (PRQR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 25 percent increase over losses of $(0.12) per share from
Benzinga Newsdesk
PRO
ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.10) per share from the same period last year.
Benzinga Newsdesk
PRO
ProQR Therapeutics Q4 EPS $(0.09) Misses $(0.08) Estimate, Sales $5.458M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 10 percent increase over losses of $(0.10) per share from
Benzinga Newsdesk
PRO
ProQR Therapeutics Q3 EPS $(0.10), Inline, Sales $2.882M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year.
Benzinga Newsdesk
PRO
ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate, Sales $4.327M Miss $4.408M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of $(0.03) per share
Benzinga Newsdesk
PRO
ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of $(0.03) per share
Benzinga Newsdesk
